BNET Industries

Market Cap:$148.4B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Pfizer Raises Quarterly Dividend 13%, See More Annual Hikes
-
REG-Pfizer Inc Pfizer Declares an 18-Cent First-Quarter 2010 Dividend
-
BRIEF: SEC probing insider-trading allegations
-
Pfizer joins partnership with Calif. firm: Collaboration planned with Crown Bioscience for cancer research
-
Research and Markets: The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to...
-
Science and Technology: Pfizer to buy Croatian drug patent
-
Bristol-Myers Squibb Raises Exchange Offer Price For Mead Johnson Shares - Update
-
'IT boosts efficiency & innovation'
-
Inspector General Saved Billions in Healthcare This Year
-
Private security firms no longer able to provide police information checks
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Market Report -- In Play PFE
-
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher's Disease
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Conservationists salute two corporations
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
2009: The Year That Was For Pfizer
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
News & Analysis
Filter by
government and pfizer inc. - All News and Analysis
FDA Offers Pfizer's HIV Drug Selzentry New Life -- For All the Good It Will Do
The FDA approved Pfizer's anti-HIV drug Selzentry for expanded use in combination with other antiretroviral agents for treatment-naïve patients who are infected with only CCR5-tropic HIV-1. Contrary to company expectations, perceived limitations of this entry inhibitor could stall efforts to facilitate usage beyond salvage therapy. by David Phillips
Auxilium Pharmaceuticals, Inc. 3Q09 (Qtr End 9/30/09) Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions Your first question comes from the line of Marshall Urist with Morgan Stanley. Please proceed. Marshall Urist - Morgan Stanley Yeah, hi guys, good morning. Couple of things, first one just from your comments on the – on the Pfizer, Pfizer said in...
Pfizer's Silence on Post-Wyeth Merger Job Cuts, Site Closures Has Everyone on Edge
Pfizer is driving everyone nuts with its silence on which sites, offices and labs it will close following its merger with Wyeth. Even the Connecticut governor doesn't know what Pfizer's plans will be, even though the state has two sites -- Groton and New London -- and 5,000 jobs at...
List of Pfizer's Trovan Victims Has Been Lost, Nigerian Officials Say
Nigerian officials have lost the list of victims to be compensated under Pfizer's $75 million settlement with the Kano State government following the Trovan meningitis trials in that country. The money was to be paid by Oct. 15, but the process has now been stretched out a further three months...
Pfizer's Lawyers Play Musical Chairs in Wake of Bextra Settlement
Pfizer's lawyers have found themselves playing musical chairs since the $2.3 billion Bextra settlement. The general counsel's office has been stripped of part of its compliance role under a new corporate integrity agreement with the government stemming from the Bextra scandal. More recently, senior corporate counsel Paulette Morgan left Pfizer...
Pfizer Used Docs Accused of Misconduct to Prep Geodon Submission to FDA
Pfizer used three physicians who have since been accused of misconduct to prepare submissions to the FDA for the approval of the antipsychotic Geodon, according to a whistleblower lawsuit brought by a Harrisburg, Pa., doctor. by Jim Edwards
Pfizer Stock Shrugs Off $2.3B Bextra Fine; Can Anything Deter Off-Label Promotion?
Pfizer's $2.3 billion settlement with the government over its mismarketing of Bextra is significant, but a look at other liabilities and settlements suggests that stock prices are unaffected by government discipline of off-label marketing. by Jim Edwards
Pfizer Exec Says FDA's Lack of Social Media Guidance Is "a Problem"
Pfizer PR chief Ray Kerins blasted the FDA's lack of guidance on social media as "a problem" at a recent conference: "There actually are no guidelines for corporations like Pfizer in what we can and cannot do in social media, and that's a problem." by Jim Edwards
Venezuela to Pfizer: "Nice Factory Ya Got Here. Be a Shame if Anything Happened to It."
Pity poor Pfizer as it tries to perform a simple operations consolidation between two factories in Venezuela. The government just demanded $17 million in back taxes after auditing the company, and is threatening to seize and nationalize one of its factories in "a few days." Pfizer has offered to sell...
Pfizer "Bribe" Scandal in Philippines Heats Up; Company Offered Posters to the President
An allegation that Pfizer attempted to "bribe" the government of the Philippines with 5 million discount cards to get a price control law postponed has developed into a full-blown scandal in the archipelago nation. Pfizer denies there was an attempt to bribe anyone, and yesterday described the allegations as "absurd."...
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes

